Posted by Michael Wonder on 02 Oct 2024
NICE ready to work with company to address uncertainty in evidence for elacestrant for advanced breast cancer
1 October 2024 - Today NICE is consulting on draft guidance that does not recommend elacestrant for treating a type of advanced breast cancer.
The draft guidance, which is open for public consultation until 22 October, does not recommend elacestrant for treating oestrogen receptor-positive, human epidermal growth factor receptor 2 negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation.
